ALX ONCOLOGY HOLDINGS INC

ALXONASDAQ

🏆 #3757 by market capEarnings Nov 5US Equity

$1.34▼ $0.06 (−4.29%)

Market closed · at close

🔔

Track ALXO

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 4.3%

7d▼ 7.6%

14d▼ 24.1%

30d▼ 30.9%

ytd▲ 18.1%

1y▼ 26.2%

🏦Market Cap

$180M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

9.0%

Thin

💵FCF Margin

—

⚖️P/S Ratio

51.4x

Expensive

Otter Score

Good

Trading Snapshot

Day Range: $1.34 – $1.36
52-Week Range: $1.05 – $2.66
Volume: $2.76B
Avg Volume: $2.05B
Shares Outstanding: 134.6M
Next Earnings: Dec 9, 2026

Fundamentals Snapshot

Annual Revenue: $4M
Last Q Revenue: $901,771
P/E Ratio: —
P/S Ratio: 51.4x
EPS (TTM): $-1.14
Dividend Yield: —
Dilution (1yr): +2.8%

Why Investors Own ALXO

✓High-growth profile — revenue up +58.2% YoY with expanding US Equity exposure.
✓Healthy economics — 47% gross margin and 12% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ALX ONCOLOGY HOLDINGS INC

ALXO

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$104M▼ −27.0% YoY

Free Cash Flow

−$84M▼ −31.1% YoY

Shares Outstanding

54.3M▲ +2.8% YoY

Net Cash

$11M▲ +$3M YoY

StockOtter · stockotter.space

About ALX ONCOLOGY HOLDINGS INC

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

🦦